Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 6/20 | 0.47 |
| ▸ | CA1 | P00915 | 6/20 | 0.47 |
| ▸ | CA2 | P00918 | 6/20 | 0.47 |
| ▸ | CA9 | Q16790 | 6/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 5/20 | 0.42 |
| ▸ | STK17B | O94768 | 1/20 | 0.42 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | FPR3 | P25089 | 2/20 | 0.40 |
| ▸ | FPR2 | P25090 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31059796 | 0.83 | CA12 (0.43) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL16065054 | 0.82 | CA12 (0.51) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL16065044 | 0.82 | CA12 (0.51) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL2530975 | 0.79 | CA12 (0.58) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL29790576 | 0.76 | CA12 (0.46) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL24741781 | 0.76 | CA12 (0.50) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL28445733 | 0.76 | CA12 (0.43) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL25028474 | 0.75 | CA12 (0.70) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL15805865 | 0.75 | CA12 (0.57) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL15036785 | 0.75 | CA12 (0.57) | CA12CA1CA2CA9TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970334-B1 | MACROCYCLIC COMPOUNDS AS IRAK4 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | BIOGEN MA INC (US) | 2018-05-23 | — | — | EP | disclosed |